Cancer vaccines

DGAP-News: DEFENCE THERAPEUTICS ACCUVAC-D001 CANCER VACCINE GENERATES EFFECTIVE LONG-LASTING ANTI-TUMORAL RESPONSE

Retrieved on: 
Tuesday, May 25, 2021
Medical specialties, Vaccination, Clinical medicine, Medicine, Cancer vaccines, Immunology, Vaccine, Virology, Cancer vaccine, Therapeutic vaccines, Dendritic cell

Vancouver, BC, Canada, May 25, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is pleased to announce the completion of its AccuVAC-D001 cancer vaccine pre-clinical study.

Key Points: 
  • Vancouver, BC, Canada, May 25, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is pleased to announce the completion of its AccuVAC-D001 cancer vaccine pre-clinical study.
  • The AccuVAC-D001 cancer vaccine demonstrated a 70% cure rate of mice with pre-established solid tumors, this AccuVAC-D001 cancer vaccine confirms an effective anti-tumoral response.
  • Non-specific degradation of endocytosed cancer antigens by endo-lysosomal organelles in dendritic cells (DCs) is a major limitation in the field of cancer vaccination.
  • This puts Defence and its technology on the path for future development of universal therapeutic vaccines for cancer and infectious diseases vaccines", says Mr. Plouffe, CEO of Defence Therapeutics.

Perlmutter Cancer Center at NYU Langone Health Joins Call For Urgent Action To Get Cancer-Preventing HPV Vaccination Back On Track

Retrieved on: 
Friday, May 21, 2021
Cancer, Clinical medicine, Papillomavirus, Vaccination, Infectious causes of cancer, Cancer vaccines, Vaccines, Gynaecological cancer, HPV vaccine, Human papillomavirus infection, Vaccine, Gardasil

Despite those staggering figures and the availability of a vaccine to prevent HPV infections, HPV vaccination rates remain significantly lower than other recommended adolescent vaccines in the U.S.

Key Points: 
  • Despite those staggering figures and the availability of a vaccine to prevent HPV infections, HPV vaccination rates remain significantly lower than other recommended adolescent vaccines in the U.S.
  • Even before the COVID-19 pandemic, HPV vaccination rates lagged far behind other vaccines and other countries\' HPV vaccination rates.
  • Catch-up HPV vaccination is recommended through age 26.\nNCI Cancer Centers strongly encourage parents to vaccinate their adolescents as soon as possible.
  • "\nMore information on HPV is available from the CDC and National HPV Vaccination Roundtable .

MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Prostate cancer, MCRPC, Cancer, Cancer vaccines, Clinical medicine, Prostvac, Medicine

This included six patients at the 4.0 mg/kg cohort enrolled subsequent to the 2020 ASCO poster presentation.

Key Points: 
  • This included six patients at the 4.0 mg/kg cohort enrolled subsequent to the 2020 ASCO poster presentation.
  • Preliminary evidence of anti-tumor activity by MGC018 has been observed, most notably in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).
  • Of the nine patients with mCRPC, eight were evaluated for tumor response, all of whom demonstrated a best response of stable disease.
  • Two of these eight patients had measurable disease; both had reductions in target lesions, including a 29% reduction in one patient.

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Medical specialties, Clinical medicine, Vaccines, Cancer vaccines, Genomics, Applied genetics, Biotechnology, Immunogenicity, Mutanome, Epitope, Antigen

b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.

Key Points: 
  • b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.
  • This study demonstrates a superior method of survival analysis for cancer patients using EVT\'s Ancer platform.
  • EVT spun-off from EpiVax, Inc. in 2017 to apply EpiVax tools to clinical research.\nBuilt on validated in silico tools EpiMatrix and JanusMatrix , Ancer analyzesindividual cancer mutanomes to definethe presence of T cell epitopes likely to be immunogenic.
  • EVT\'s pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.\n'

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Medical specialties, Clinical medicine, Vaccines, Cancer vaccines, Genomics, Applied genetics, Biotechnology, Immunogenicity, Mutanome, Antigen, Cancer vaccine

b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.

Key Points: 
  • b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.
  • This study demonstrates a superior method of survival analysis for cancer patients using EVT\'s Ancer platform.
  • EVT spun-off from EpiVax, Inc. in 2017 to apply EpiVax tools to clinical research.\nEpiVax Therapeutics researchers develop improved method for cancer survival prediction.\nBuilt on validated in silico tools EpiMatrix and JanusMatrix , Ancer analyzesindividual cancer mutanomes to definethe presence of T cell epitopes likely to be immunogenic.
  • EVT\'s pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/improving-cancer-survival-predic...\n'

Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 5, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Cancer vaccines, Genomics, Medical genetics, Vaccines

b'LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021, at 9:30 a.m.

Key Points: 
  • b'LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021, at 9:30 a.m.
  • ET / 2:30 p.m. BST.\nA live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles websit e.\nAchilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.
  • The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma.
  • Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS\xe2\x84\xa2 bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.\n'

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

Retrieved on: 
Tuesday, May 4, 2021
Vaccination, Virology, Cancer vaccines, Vaccine, Therapeutic vaccines, Cancer vaccine

b'LEIDEN, Netherlands, May 4, 2021 /PRNewswire/ --ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company dedicated to developing immunotherapeutics for oncology and infectious diseases,announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines.

Key Points: 
  • b'LEIDEN, Netherlands, May 4, 2021 /PRNewswire/ --ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company dedicated to developing immunotherapeutics for oncology and infectious diseases,announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines.
  • This is the link to the online article: https://www.nature.com/articles/s41568-021-00346-0 .\nThe Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine trials.
  • Kees Melief, Chief Scientific Officer at ISA Pharmaceuticals, said: "Therapeutic cancer vaccines have undergone a resurgence in the past years.
  • It shows that targeted activation of the immune system by therapeutic vaccines can play an important role in beating cancer.

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

Retrieved on: 
Tuesday, May 4, 2021
Vaccination, Virology, Cancer vaccines, Vaccine, Therapeutic vaccines, Cancer vaccine

b'LEIDEN, Netherlands, May 4, 2021 /PRNewswire/ --ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company dedicated to developing immunotherapeutics for oncology and infectious diseases,announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines.

Key Points: 
  • b'LEIDEN, Netherlands, May 4, 2021 /PRNewswire/ --ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company dedicated to developing immunotherapeutics for oncology and infectious diseases,announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines.
  • This is the link to the online article: https://www.nature.com/articles/s41568-021-00346-0 .\nThe Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine trials.
  • Kees Melief, Chief Scientific Officer at ISA Pharmaceuticals, said: "Therapeutic cancer vaccines have undergone a resurgence in the past years.
  • It shows that targeted activation of the immune system by therapeutic vaccines can play an important role in beating cancer.

The American Cancer Society Encourages Parents to Reschedule Missed Vaccine Visits for Kids

Retrieved on: 
Monday, May 3, 2021
Cancer, Papillomavirus, Clinical medicine, Medical specialties, Infectious causes of cancer, Cancer vaccines, Vaccines, Vaccination, Human papillomavirus infection, HPV vaccine, Vaccine, Gardasil

Dataindicate that the COVID-19 pandemic is having a negative effect on vaccination rates.

Key Points: 
  • Dataindicate that the COVID-19 pandemic is having a negative effect on vaccination rates.
  • Most infections become undetectable, but some can go on to cause cancer.\nHPV vaccination works best when given between ages 9 and 12.
  • Children and young adults age 13 through 26 who have not been vaccinated, or who haven\'t gotten all their doses, should get the vaccine as soon as possible.
  • HPV vaccination helps protect boys from cancers of the throat, penis, and anus later in life.

Global Peptide Cancer Vaccine Market Clinical Trials Research Outlook 2026

Retrieved on: 
Thursday, April 22, 2021
Medicine, Clinical medicine, Vaccines, Medical specialties, Vaccination, Vaccine, Virology, Cancer vaccines, Peptide vaccine, Medical research, Tumor antigen vaccine, Gp100:209-217

b'"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" Report Highlights:\nGlobal Peptide Cancer Drugs Market Opportunity: >USD 20 Billion\nGlobal Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase\nNumber Of Peptide Vaccines In Pipeline: >90\n"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global Peptide Cancer Vaccine market and its impact on the global pharmaceutical market landscape.

Key Points: 
  • b'"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" Report Highlights:\nGlobal Peptide Cancer Drugs Market Opportunity: >USD 20 Billion\nGlobal Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase\nNumber Of Peptide Vaccines In Pipeline: >90\n"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global Peptide Cancer Vaccine market and its impact on the global pharmaceutical market landscape.
  • Currently, GV10001 is the only peptide based vaccine approved in Korea for the management of pancreatic cancer.
  • The high growth rate is mainly attributed to the high prevalence of cancer, robust clinical pipeline of vaccines and the safety and cost-efficacy of peptide based vaccines.\nIn terms of geography, it is expected that North America will dominate the global peptide cancer vaccine market landscape after the commercial launch of first peptide cancer vaccine in the region.
  • In coming years, the market will witness rapid approval of several peptide based cancer vaccines which will boost the growth of market.